Bremen-Mitte Clinic
En Allemagne, le traitement par Xofigo Radium-223 coûte généralement entre $50,000 et $80,000. Le tarif global dépend du nombre de cycles et des examens d'imagerie nécessaires. En France, les patients paient souvent environ $16,500 pour des thérapies similaires. L'Allemagne permet une économie importante d'environ 0 %. Le paiement inclut le radiopharmaceutique, son administration par un spécialiste et le suivi sanguin régulier.
Avis d'expert Bookimed : Choisir un hôpital classé par Focus, comme la clinique Bremen-Mitte, garantit une oncologie de haut niveau. Cet établissement soigne 40 000 patients par an et possède une certification ISO. Les patients avertis doivent vérifier si le devis initial couvre l'intégralité des six cycles. Certains centres allemands incluent le suivi dans leur forfait de base. Cela reste plus avantageux que de régler chaque séance individuellement.
Pourquoi choisir l'Allemagne pour le traitement au Xofigo Radium-223 ?
Accédez à des solutions avancées au Xofigo Radium-223 dans des cliniques de confiance .
| Turquie | Espagne | Allemagne | |
| Xofigo Radium-223 | de $7,000 | de $14,000 | de $50,000 |
Bookimed ne facture pas de frais supplémentaires pour les prix des Xofigo Radium-223. Les tarifs sont issus des listes de prix officielles des cliniques. Vous payez directement à la clinique lors de votre arrivée pour votre Xofigo Radium-223.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans Xofigo Radium-223 et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de Xofigo Radium-223.
Jour 1 - Arrivée
Jour 2 - Pré-opération
Jour 3 - Traitement Xofigo Radium-223
Jour 4 - Post-opération
Semaine 1 à 4 - Période de traitement
Semaine 5-8 - Rééducation
Veuillez noter que l'expérience de chaque patient avec Xofigo Radium-223 peut varier en fonction des circonstances individuelles.
Xofigo is a radiopharmaceutical injection using radium-223 to treat advanced prostate cancer. It mimics calcium to target bone metastases directly. This alpha-emitting radiation destroys cancer cells in the bones while sparing surrounding healthy tissue, typically delivered in 6 intravenous sessions every 4 weeks.
Bookimed Expert Insight: While many global centers use general oncology departments for radiopharmaceuticals, German institutions like Bremen-Mitte Clinic offer specialized nuclear medicine units. These ISO-accredited facilities integrate Xofigo with advanced diagnostics to monitor bone marrow health precisely. Choosing a clinic within a large network like Gesundheit Nord ensures multidisciplinary support if blood counts drop during the 6-month cycle.
Patient Consensus: Patients often emphasize that this therapy is a management strategy rather than a cure. Many report that stabilizing bone pain becomes the primary measure of success during the treatment period.
Xofigo treatment carries serious risks including severe bone marrow suppression, increased bone fracture rates, and embryo-fetal toxicity. This radioactive therapeutic agent significantly lowers red blood cell, white blood cell, and platelet counts. Clinical trials show 57% of patients experience Grade 3 or 4 adverse events.
Bookimed Expert Insight: German clinics like Bremen-Mitte emphasize strict hematological monitoring for patients with extensive skeletal metastases. Data suggests that patients with baseline anemia face much higher risks of early treatment termination. Leading German centers typically mandate weekly blood counts rather than monthly to catch marrow failure early.
Patient Consensus: Patients frequently report that severe fatigue and temporary bone pain are the most immediate daily challenges. Many advise discussing bone-protective medications beforehand to specifically minimize the heightened risk of skeletal fractures during therapy.
Xofigo relieves bone pain by acting as a calcium mimic that targets high-turnover areas near metastases. This targeted alpha therapy delivers localized, high-energy radiation. It destroys cancer cells while sparing healthy tissue. German clinics like Bremen-Mitte use this method to extend survival and reduce symptomatic discomfort.
Bookimed Expert Insight: While Xofigo targets bone lesions, German centers often combine it with advanced blood monitoring. Clinics like Bremen-Mitte, ranked by Focus magazine, prioritize bone-dominant cases for better outcomes. Most patients should expect a 24-week timeline to complete the full therapeutic course effectively.
Patient Consensus: Many patients notice improved mobility and gradual pain reduction after several treatment cycles. It works best for bone-specific disease and requires regular blood tests to manage potential fatigue.
Xofigo is administered as a slow intravenous injection into a vein by healthcare professionals. The procedure takes approximately 1 minute in a specialized nuclear medicine or oncology outpatient setting. Patients typically receive 6 total injections, with each treatment session scheduled 4 weeks apart.
Bookimed Expert Insight: While the injection lasts 60 seconds, expect to spend 2 to 3 hours at clinics like Bremen-Mitte. German protocols require rigorous pre-dose lab verification and radioisotope calibration. This precision ensures the dosage matches your body weight exactly before administration begins.
Patient Consensus: Treatment feels like a standard IV drip rather than aggressive chemotherapy. Most emphasize requesting written radiation safety instructions for home hygiene and family contact precautions after each session.
Xofigo therapy requires strict hygiene for 7 days after injection to manage radioactive bodily fluids. Patients must flush toilets twice and wash hands thoroughly. While physical proximity is low-risk, travelers should carry a medical card because airport sensors may detect lingering radiation levels from the isotope.
Bookimed Expert Insight: German clinics like Bremen-Mitte maintain high safety standards under ISO International Standards. Data shows radiation teams often provide varying local guidance. Patients should request a written home-care plan directly from their nuclear medicine department. Most find these protocols less disruptive than expected once a bathroom clean-path is established.
Patient Consensus: The most significant task is preparing for accidental spills with gloves and disposable towels. Patients report that the rules feel manageable and do not prevent normal family life.
Algeta ASA, a Norwegian biotechnology company, developed Xofigo (radium-223 dichloride). Bayer HealthCare currently markets the therapy globally following a 2009 partnership. Initial production began in Oslo, Norway, while additional manufacturing facilities now operate in the United States to support global distribution.
Bookimed Expert Insight: While Xofigo was developed in Norway, its treatment availability is highly concentrated in Germany. Clinics like Bremen-Mitte Clinic leverage Bayer’s local supply chains. This ensures consistent access to this specialized isotope therapy in ISO-certified German hospitals. Patients often find the logistics more streamlined here than in other regions.
Patient Consensus: Patients prioritize finding nuclear medicine centers with strict blood count monitoring protocols. Most focus on treatment logistics rather than the drug's manufacturing origin.